Both the PK and PD characteristics were consistent between the Caucasian and Asian populations. == Conclusion == The targetmediated drug disposition model successfully described the PK and PD characteristics of evolocumab, and this analysis found no significant differences in the PK/PD relationship for its LDLC lowering effects between Caucasians and Asians. Keywords:biopharmaceutics, cardiovascular, modelling and simulation, monoclonal antibodies, pharmacokineticpharmacodynamic == What is Already Known about the Subject == Evolocumab (Repatha) is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of hypercholesterolaemia and it has been approved in many countries using two dose regimens of 140mg every 2weeks, and 420mg monthly. A targetmediated drug disposition model was used to describe the pharmacokinetics (PK) and pharmacodynamics (PD) of evolocumab and captured its binding and removal with PCSK9 and the subsequent lowering of lowdensity lipoprotein cholesterol . Plasma levels CGP 36742 of PCSK9 vary over almost a 100fold range between sexes and among different ethnicities. l1. Rabbit Polyclonal to 5-HT-2C Both the PK and PD characteristics were consistent between the Caucasian and Asian populations. == Conclusion == The targetmediated drug disposition model successfully described the PK and PD characteristics of evolocumab, and this analysis found no significant differences in the PK/PD relationship for its LDLC lowering effects between Caucasians and Asians. Keywords:biopharmaceutics, cardiovascular, modelling and simulation, monoclonal antibodies, pharmacokineticpharmacodynamic == What is Already Known about the Subject == Evolocumab (Repatha) is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of hypercholesterolaemia and it has been approved in many countries using two dose regimens of 140 mg every 2 weeks, and 420 mg monthly. A targetmediated drug disposition model was used to describe the pharmacokinetics (PK) and pharmacodynamics (PD) of evolocumab and captured its binding and removal with PCSK9 and the subsequent lowering of lowdensity lipoprotein cholesterol . Plasma levels of PCSK9 vary over almost a 100fold range between sexes and among different ethnicities. Covariates, such as target expression levels and body weight, are known to lead to different PK profiles of monoclonal antibody therapeutics among different ethnic groups. == What this CGP 36742 Study Adds == This study analysed pooled data obtained in several Phase 1 clinical trials from different countries using a targetmediated drug disposition model to assess the ethnic differences of evolocumab. The results showed no ethnic differences in the PK (in both nonspecific and specific aspects) or PD characteristics of evolocumab. There is no apparent need to modify the dose or dose regimen of evolocumab for Asian subjects CGP 36742 with hypercholesterolaemia since the drug has no known offtarget effects at Food and Drug Administrantionapproved doses and since no ethnic difference were found in the current investigation. == Introduction == Evolocumabis a human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) that is used for the therapeutic treatment of hypercholesterolaemia and the prevention of heart attack and stroke1,2. The recommended therapeutic dose regimen for evolocumab is 140 mg once every 2 weeks (Q2W) or 420 mg once every month (QM), both administered subcutaneously (SC). In human body, the liver is responsible for catabolism of plasma lowdensity lipoprotein (LDL). Hepatocytes express lowdensity lipoprotein receptor (LDLR) that binds LDL and removes it from the plasma. Upon internalization, vesicles containing the LDLLDLR CGP 36742 complex fuse with endosomes. PCSK9 is a protein that regulates the expression of LDLR in the liver. It binds to LDLRs on the surface of the hepatocyte and is internalized with the LDLLDLR complex. The LDLRPCSK9 complex is routed to the lysosome for degradation, thereby preventing the cycling of LDLR back to the hepatocyte surface. The reduced concentration of LDLR on the surface of hepatocytes results in a lower rate of plasma LDL elimination. Evolocumab specifically binds to human PCSK9 and prevents it from interacting with LDLR, which plays a critical role in the maintenance of the cellular and whole body cholesterol balance by regulating plasma LDLcholesterol (LDLC) levels3,4,5,6,7. CGP 36742 The pharmacokinetic (PK) and pharmacodynamic (PD) properties of evolocumab have been investigated in healthy subjects and subjects with hypercholesterolaemia using a targetmediated drug disposition (TMDD) model in previous research8. The drug disposition was characterized by a linear clearance, which is consistent with the common approach used for other monoclonal antibodies (mAbs). The time course of LDLC reduction was described by an indirect response model with the elimination rate of LDLC being modulated by unbound PCSK9. PK.